For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Respiratory drugs - Independent medicine & health information for consumers & professionals Respiratory drugs — medicine information
Latest independent drug information about respiratory drugs and treatments, written and reviewed by experts in Australia.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Webinar | Connect in real time with expert panellists on the use of diagnostic imaging in respiratory tract infections | Event | Health Professionals | 2012-04-01 00:00:00 |
| Antibiotics - controlling resistance | We review the latest evidence about individual antibiotic resistance and using patient-centred communication to improve prescribing | Professional publication - NPS News | Health Professionals | 2012-02-01 00:00:00 |
| Online Clinical e-Audit | This online Clinical e-Audit enables you to review your current practice, consider implementing changes to practice and reflect on areas for ongoing improvement. | Professional activity - Clinical audit | Health Professionals | 2012-02-27 00:00:00 |
| Upper respiratory tract infection - managing symptoms | A patient information leaflet that doctors can use to reinforce verbal instructions regarding symptomatic management for respiratory tract infections where antibiotics may not be required. | Professional tool - Patient leaflet | Consumers,Health Professionals | 2006-01-01 00:00:00 |
| Case study 72: Management of rhinosinusitis | Jessica, a 26-year-old student, presents to you complaining of a 4 day history of coloured nasal discharge, headache, lethargy and sneezing. | Professional activity - Case study | Health Professionals | 2012-02-01 00:00:00 |
| Indacaterol (Onbrez) for chronic obstructive pulmonary disease (COPD) | Read our information on indacaterol (Onbrez), a new maintenance inhaler for chronic obstructive pulmonary disease (COPD): side effects & benefits, who can use it & other treatment options. | Consumer publication - Medicine Update | Consumers | 2011-12-01 00:00:00 |
| Budesonide with eformoterol (Symbicort Turbuhaler) for asthma and chronic obstructive pulmonary disease | Information on budesonide with eformoterol in treatment of moderate to severe chronic obstructive pulmonary disease in people with frequent symptoms despite long-acting bronchodilator use and/or a history of recurrent exacerbations. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2011-12-01 00:00:00 |
| Quality use of inhaled medicines in COPD | Clinical audit used to assist pharmacists to identify counselling points for patients using inhaled medicines and reinforce key points about COPD management. | Professional activity - Pharmacy Practice Review | Health Professionals | 2008-04-26 00:00:00 |
| Indicators of Quality Prescribing: 11 | Indicators of Quality Prescribing: Indicator 11 Antibiotics (Cephalexin). This indicator asks practices what percentage of prescriptions for cephalexin had as the indication non-specific URTI, pharyngitis, tonsillitis, acute otitis media, sinusitis or acute bronchitis. | Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
| Indicators of Quality Prescribing: 9 | ndicators of Quality Prescribing: Indicator 9 Antibiotics (Non-specific URTI). This indicator asks practices what percentage of patients are prescribed an antibiotic for a non-specific upper respiratory tract infection (URTI). | Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
| Common inhaler devices chart | A chart showing common inhaler devices with guides to help patients optimise their use of inhaled medicines. | Tool - Health Professional | Health Professionals | 2006-05-08 00:00:00 |
| Case study 53 report: Maximising benefits with inhaled therapy | Jane, a 60-year-old primary school teacher with stable COPD (diagnosed 2 years ago) presents with a wheeze and increased breathlessness, especially at night, several times over the past week following a viral infection. | Professional activity - Case study report | Health Professionals | 2008-08-19 00:00:00 |
| Case study 53: Maximising benefits with inhaled therapy | Jane, a 60-year-old primary school teacher with stable COPD (diagnosed 2 years ago) presents with a wheeze and increased breathlessness, especially at night, several times over the past week following a viral infection. | Professional activity - Case study | Health Professionals | 2008-06-01 00:00:00 |
| NPS Evaluation Report No. 2: November 2000 | Evaluation of NPS including current priorities, antibiotics for URTIs as a target therapeutic area, evaluation of divisional case studies, and methodological challenges in evaluation. | Corporate publication - Evaluation report | Research & Evaluation community | 2000-11-01 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
